about
Optimising treatment of end-stage renal disease in the elderlyEncapsulating peritoneal sclerosis: what have we learned?The role of peritoneal dialysis in modern renal replacement therapy.Determinants of quality of life in advanced kidney disease: time to screen?Ethnic and cultural challenges at the end of life: setting the scene.Peritoneal or hemodialysis for the frail elderly patient, the choice of 2 evils?Empirical aminoglycosides for peritonitis do not affect residual renal function.Supportive care for people with kidney disease: ethnic and cultural challenges.Peritoneal dialysis: older patients report better quality of life than younger.Influence of psychosocial factors on the energy and protein intake of older people on dialysis.Quality of life at end of life.Epidemiology and management of end-stage renal disease in the elderly.Dialysis Survivors: Clinical Status of Patients on Treatment for More than 10 YearsCKD and frailty: outcomes from a quality initiative for older patientsOxford Handbook of DialysisDialysis in the nursing home: Caring for patients with ESRDCognitive Impairment in Elderly Renal Inpatients: An Under-Identified PhenomenonWhat can we do to improve quality of life for the elderly chronic kidney disease patient?Extended access to peritoneal dialysis for frail older patientsPeritoneal DialysisOxford Handbook of DialysisCAPD, Protective against Developing Dialysis-Associated Amyloid?Is the Renin-Angiotensin-Aldosterone System Involved in the Sodium Retention in the Nephrotic Syndrome?Lack of Effect of Captopril on the Sodium Retention of the Nephrotic SyndromePeritoneal Dialysis ClearancesRenal Function in Rats with Acute Medullary InjurySodium Retention in Nephrotic Syndrome Is Due to an Intrarenal Defect: Evidence from Steroid-Induced RemissionTechnetium-99-Labelled Methylene Diphosphonate Uptake Scans in Patients with Dialysis ArthropathyEnd of Life Care in NephrologyRenal Tumours in Dialysis Patients: Who Should We Screen?Peritoneal DialysisRENAL REPLACEMENT THERAPY IN ACUTE RENAL FAILUREAn opportune time to develop new strategies against repeat peritonitis in patients on peritoneal dialysis?Glomerulonephritis Associated with Permanent Pacemaker EndocarditisPersistence of Dialysis Amyloid after Renal TransplantationDelivering peritoneal dialysis for the multimorbid, frail and palliative patientPerson-centered peritoneal dialysis prescription and the role of shared decision-makingInternational Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysisLong-term outcomes in patients with encapsulating peritoneal sclerosis managed with nutritional supportInternational Society for Peritoneal Dialysis Practice Recommendations: The view of the person who is doing or who has done peritoneal dialysis
P50
Q26823431-94C9B584-F344-434E-84DF-2C27F143E9F1Q37857973-4C46BA26-1164-4468-B42C-82D30FEA7294Q38125989-70B60D85-9504-49D1-9726-18D23C7241FCQ38198981-48D4AE8B-C3E6-419E-AFAC-FEE14FD1E42BQ38245820-92269B73-B8B2-4FA2-B4FA-82DD972CF54EQ38988803-C7B77E0F-EF52-4E58-869D-2F5D668588BAQ44338076-880E0E53-59E1-4412-A081-CEE76A4A529CQ46607340-A5EC6C1C-C24E-4635-9111-C512D7A5BC39Q48052564-DDA54B72-3869-4F8B-82FF-F65FBCD72309Q48252352-A0E5CFB3-A49C-41A0-89BC-6AC0FC8E243BQ48478342-DF9EBE74-4106-4996-92EC-9B970132642CQ48602020-77CB17B9-5DA4-40EC-90B5-6462F01961B0Q57608140-375EAE85-916A-4D8E-B787-DB05484369E2Q59647194-0064B103-7BA2-4C3E-B06F-EE5812AB39CCQ59647195-1862F4C3-4582-49E9-ADD7-880DEC6F3F02Q59647201-4FC6E27E-7E0E-4BEC-BAFA-AB5BCC20BBABQ59647202-E3BBC4F9-CF97-45F9-BCBD-B03A2BA054FFQ59647211-0BED5B2A-CE13-4266-A858-8FA0ADE3BCD3Q59647219-F14595E2-BC31-46E0-8BDA-617A36376075Q59647220-1D5E52B1-1E7E-40FE-B09B-E74CB01F54CCQ59647222-289678DE-C939-4A50-9B56-E1C96A71B20CQ59647226-3B680ACD-E8E0-4088-8A8E-4D572ED2B208Q59647228-FA07D8E3-E1D6-498E-8CCB-0C99B18F14F9Q59647229-684CC057-5E85-4951-9083-6F5C282FEF84Q59647230-BF026BE0-F1F5-4545-A24C-65BAAC41E4E2Q59647231-27AD9821-545A-4A35-AC45-C588BB0ACD6EQ59647233-24E12483-71A7-425C-BF7C-91BB110EE204Q59647234-15561C89-9CDC-4A6A-A6D6-1EFFE2F26B23Q59647236-88AC7A22-3317-4101-9D18-F47BB7C86AD5Q59647238-180E87FC-63E4-4FBC-BB88-E2EBA0527D37Q59647240-D30640A8-D730-4F0E-B11B-F57DB4AB9CDAQ59647241-F6184B1C-8A3D-4114-807B-D3936C24E66FQ59647243-D6AC535A-6C7A-4D96-AAD7-7D9E0BE28079Q59647244-AD3573A3-2CBB-4D4C-947B-435016B51531Q59647245-85677184-EFE2-47D6-9DE9-393D557774A5Q89733931-7F6CF67B-A83B-4935-8203-D5ECCC77C16BQ89733956-5F1A2908-4051-4665-BE59-BD1DFAD4A85DQ89733959-A003E299-6D89-4C03-8559-D2D0675187E7Q89751211-65AED6D2-EF14-4986-865D-B13A3A088699Q92008696-E27235BB-529D-403C-B890-86D157BE6594
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Edwina A Brown
@ast
Edwina A Brown
@en
Edwina A Brown
@es
Edwina A Brown
@nl
Edwina A Brown
@sl
type
label
Edwina A Brown
@ast
Edwina A Brown
@en
Edwina A Brown
@es
Edwina A Brown
@nl
Edwina A Brown
@sl
prefLabel
Edwina A Brown
@ast
Edwina A Brown
@en
Edwina A Brown
@es
Edwina A Brown
@nl
Edwina A Brown
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0002-4453-6486
P734
P7859
lccn-n98801363